Moderna Inc. said Thursday a Phase 3 trial of its next-generation COVID-19 vaccine met its main goal and showed higher ...

Novavax's traditional protein-based shot offers an alternative vaccine technology to those that are based on messenger RNA - Moderna's Spikevax and Comirnaty, which is jointly developed by Pfizer ...

Moderna’s Spikevax and Pfizer’s Comirnaty are available for those 12-years and older at GIANT and MARTAIN’S pharmacies.

Spikevax 2024-2025 formula expected to be available in pharmacies and care settings across the U.S. in the days immediately following approval CAMBRIDGE, MA / ACCESSWIRE / August 22, 2024 ...

Moderna said the Spikevax 2024-2025 formula is expected to be available across the U.S. in the days immediately following approval. Pfizer also said shipping will begin immediately. Thursday ...

Also included, are Comirnaty and Spikevax, both of which are approved for people 12 and older. Here's what else to know about about the updated vaccine. Walgreens and CVS previously told USA TODAY ...

Moderna's Spikevax KP.2 targets the KP.2 variant of the virus. The U.S. Food and Drug Administration has also approved the shot, as well as updated vaccines from Pfizer and BioNTech. Moderna (MRNA ...

Moderna developed the Spikevax COVID-19 vaccine, and regulators approved this year its vaccine for RSV or respiratory syncytial virus. The company also has a combination flu/COVID vaccine and an ...

Opens in a new tab or window The FDA approved and granted emergency use authorization for updated 2024-2025 mRNA COVID-19 vaccines from Moderna (Spikevax) and Pfizer-BioNTech (Comirnaty), the ...

Image Source: Zacks Investment Research Spikevax, targeting the variant JN.1., is currently approved in the United States, the United Kingdom, Japan and Taiwan. Last month, the FDA approved ...

Until now, Canada has only had access to vaccine formulas that were approved in fall 2023 and target the Omicron XBB.1.5. Moderna's latest formulation of their mRNA vaccine, Spikevax, targets the KP.2 ...